Dr. Bruce Dezube is an associate in medicine at Beth Israel Deaconess Medical Center (BIDMC) in Boston and an associate professor of medicine at Harvard Medical School. He is a prominent investigator and a major enroller in the multi-institutional AIDS Malignancy Consortium/NCI/NIH, a group whose mission is to create new approaches to therapy of AIDS-associated malignancies. He is also a founder of the NCI/NIH-funded AIDS Oncology subunit of the AIDS Malignancy Research and Treatment Center at BIDMC.

After receiving an M.A. in chemistry from Harvard University, Dr. Dezube earned his M.D. at Tufts University Medical School. His postdoctoral training included an internship and residency at Tufts-New England Medical Center and a series of fellowships at Harvard Medical School, Beth Israel Hospital and the Dana-Farber Cancer Institute in Boston. He is board-certified in internal medicine, hematology, and oncology.

Dr. Dezube is the national chair of several NIH protocols investigating the use of angiogenesis inhibitors in Kaposi's Sarcoma (KS). These trials resulted in several of the numerous reports, articles, and book chapters that he has authored and co-authored on AIDS-related malignancies. In addition, Dr. Dezube has delivered over 200 lectures and seminars and has given plenary talks on novel therapeutics for HIV disease, on international and national levels.

He has lent his time to several community service endeavors, including work with the American Cancer Society AIDS Action Committee and the New England AIDS Education and Training Center. He is a frequent reviewer for the New England Journal of Medicine and the Journal of Clinical Oncology, among others. He has been awarded the American Cancer Society's Career Development Award and the National Cancer Institute's Clinical Trials Consortium Award for AIDS-Associated Malignancies.

Dr. Dezube receives funding for his research from Agouron Pharmaceuticals, Cytran Inc., and Ligand Pharmaceuticals.